Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo Chinese For Medical Students & Physicians A complete 20-lesson, 300-page Chinese course with a companion app in 21 languages — free forever. Download the free PDF: Amedeo Chinese PDF

Autoimmune Disorders

Free Subscription Articles published in N Engl J Med Retrieve available abstracts of 128 articles: HTML format

Single Articles

June 2026
1. BASTARD P, Casanova JL
   Autoantibodies against Cytokines - From Infection to Inflammation.
   N Engl J Med. 2026;394:2270-2273.
   PubMed    
   
   
   
2. GHARAHDAGHI N, Yeh PJ, Ceron-Gutierrez L, Griffin H, et al
   Interleukin-10 Autoantibodies and HLA-DRB1*01:03 in Inflammatory Bowel Disease.
   N Engl J Med. 2026;394:2212-2222.
   PubMed     Abstract available
   
   
   
3. FERVENZA FC, Hou FF, Hao CM, Kirsztajn GM, et al
   Obinutuzumab or Tacrolimus in Primary Membranous Nephropathy.
   N Engl J Med. 2026 Jun 5. doi: 10.1056/NEJMoa2602678.
   PubMed     Abstract available
   
   
   May 2026
4. ALLENBACH Y, Benveniste O
   Inflammatory Myopathies.
   N Engl J Med. 2026;394:1925-1938.
   PubMed     Abstract available
   
   
   
5. LV J, Liu L, Wang W, Wang X, et al
   Telitacicept for IgA Nephropathy - Interim Analysis of a Phase 3 Trial.
   N Engl J Med. 2026;394:1916-1924.
   PubMed     Abstract available
   
   
   
6. LAFAYETTE R, Brenner RM, Barratt J
   Targeting CD20 versus APRIL or BAFF and APRIL for IgA Nephropathy. Reply.
   N Engl J Med. 2026;394:1962-1963.
   PubMed    
   
   
   
7. KA SM, Chen A, Wu CC
   Targeting CD20 versus APRIL or BAFF and APRIL for IgA Nephropathy.
   N Engl J Med. 2026;394:1962.
   PubMed    
   
   
   
8. LUNDBERG IE
   A Phase 3 Trial of Brepocitinib in Dermatomyositis.
   N Engl J Med. 2026;394:1953-1955.
   PubMed    
   
   
   April 2026
9. KAWANO N, Kikuchi I
   Membranoproliferative Glomerulonephritis Due to Cryoglobulinemia.
   N Engl J Med. 2026;394:1736.
   PubMed    
   
   
   
10. CUKER A, Stauch T, Cooper N, Al-Samkari H, et al
    Ianalumab plus Eltrombopag in Immune Thrombocytopenia.
    N Engl J Med. 2026;394:1503-1513.
    PubMed     Abstract available
    
    
    
11. CERQUEIRA-SILVA T, Paixao E, Franca GVA, Tenorio LXS, et al
    Risk of Guillain-Barre Syndrome after Laboratory-Confirmed Dengue Infection.
    N Engl J Med. 2026;394:1546-1548.
    PubMed    
    
    
    
12. MURRAY JA, Husby S
    Celiac Disease.
    N Engl J Med. 2026;394:1421-1429.
    PubMed     Abstract available
    
    
    
13. KUTER DJ, Miura K, Patriarca A, Pulanic D, et al
    A Phase 2 Randomized Trial of Mezagitamab in Primary Immune Thrombocytopenia.
    N Engl J Med. 2026;394:1388-1398.
    PubMed     Abstract available
    
    
    
14. XIONG H, Li R, Shi J
    CD19 CAR T-Cell Therapy for Autoimmune Hemolytic Anemia. Reply.
    N Engl J Med. 2026;394:1455.
    PubMed    
    
    
    
15. YANG S, Lu Y
    CD19 CAR T-Cell Therapy for Autoimmune Hemolytic Anemia.
    N Engl J Med. 2026;394:1455.
    PubMed    
    
    
    March 2026
16. BARRATT J, Eren N, Kashihara N, Maes B, et al
    Iptacopan in IgA Nephropathy - Final 24-Month Data.
    N Engl J Med. 2026 Mar 29. doi: 10.1056/NEJMoa2600743.
    PubMed     Abstract available
    
    
    
17. VLEUGELS RA, Paik JJ, Bauer Ventura I, Mangold AR, et al
    A Phase 3 Trial of Brepocitinib in Dermatomyositis.
    N Engl J Med. 2026 Mar 28. doi: 10.1056/NEJMoa2503531.
    PubMed     Abstract available
    
    
    
18. FURIE RA, Dall'Era M, Vital EM, Garg JP, et al
    Efficacy and Safety of Obinutuzumab in Active Systemic Lupus Erythematosus.
    N Engl J Med. 2026 Mar 6. doi: 10.1056/NEJMoa2516150.
    PubMed     Abstract available
    
    
    
19. GOTTSCHLICH A, Bucklein V, El-Marouk K, Kaiser R, et al
    Blinatumomab in Combined Immune Thrombocytopenia and Antiphospholipid Syndrome.
    N Engl J Med. 2026;394:1030-1033.
    PubMed    
    
    
    
20. HEERSPINK HJL, Birkenfeld AL, Cherney DZI, Colhoun HM, et al
    Finerenone in Type 1 Diabetes and Chronic Kidney Disease.
    N Engl J Med. 2026;394:947-957.
    PubMed     Abstract available
    
    
    February 2026
21. TONELLI M
    Targeting the Pathogenesis of IgA Nephropathy - A New Treatment Approach?
    N Engl J Med. 2026;394:712-713.
    PubMed    
    
    
    January 2026
22. LI R, Pan H, Zhang L, Ma J, et al
    CD19 CAR T-Cell Therapy for Autoimmune Hemolytic Anemia.
    N Engl J Med. 2026;394:253-267.
    PubMed     Abstract available
    
    
    November 2025
23. PERKOVIC V, Trimarchi H, Tesar V, Lafayette R, et al
    Sibeprenlimab in IgA Nephropathy - Interim Analysis of a Phase 3 Trial.
    N Engl J Med. 2025 Nov 8. doi: 10.1056/NEJMoa2512133.
    PubMed     Abstract available
    
    
    
24. LAFAYETTE R, Barbour SJ, Brenner RM, Campbell KN, et al
    A Phase 3 Trial of Atacicept in Patients with IgA Nephropathy.
    N Engl J Med. 2025 Nov 6. doi: 10.1056/NEJMoa2510198.
    PubMed     Abstract available
    
    
    October 2025
25. SCOTT J, Abers MS, Marwah HK, McCann NC, et al
    Updated Evidence for Covid-19, RSV, and Influenza Vaccines for 2025-2026.
    N Engl J Med. 2025 Oct 29. doi: 10.1056/NEJMsa2514268.
    PubMed     Abstract available
    
    
    
26. RAHIMOV F, Jacobs BM, Lee JS, Mahi NA, et al
    Common Diseases in Clinical Cohorts - Not Always What They Seem.
    N Engl J Med. 2025;393:1589-1598.
    PubMed     Abstract available
    
    
    
27. VAN VOLLENHOVEN RF, Wang L, Merrill JT, Liu Y, et al
    A Phase 3 Trial of Telitacicept for Systemic Lupus Erythematosus.
    N Engl J Med. 2025;393:1475-1485.
    PubMed     Abstract available
    
    
    
28. BUCCI L, Boltz S, Hagen M, Tur C, et al
    BCMA T-Cell Engager Therapy in Patients with Refractory Autoimmune Disease.
    N Engl J Med. 2025;393:1544-1547.
    PubMed    
    
    
    September 2025
29. WANG Q, Xiao ZX, Zheng X, Wang G, et al
    In Vivo CD19 CAR T-Cell Therapy for Refractory Systemic Lupus Erythematosus.
    N Engl J Med. 2025 Sep 17. doi: 10.1056/NEJMc2509522.
    PubMed    
    
    
    
30. CARLSSON PO, Hu X, Scholz H, Ingvast S, et al
    Survival of Transplanted Allogeneic Beta Cells with No Immunosuppression.
    N Engl J Med. 2025;393:887-894.
    PubMed     Abstract available
    
    
    August 2025
31. TRAPNELL BC, Inoue Y, Bonella F, Wang T, et al
    Phase 3 Trial of Inhaled Molgramostim in Autoimmune Pulmonary Alveolar Proteinosis.
    N Engl J Med. 2025;393:764-773.
    PubMed     Abstract available
    
    
    
32. SEYMOUR JF
    GM-CSF in Autoimmune Pulmonary Alveolar Proteinosis.
    N Engl J Med. 2025;393:812-816.
    PubMed    
    
    
    July 2025
33. FURIE RA, Rovin BH, Pendergraft WF 3rd
    Efficacy and Safety of Obinutuzumab in Active Lupus Nephritis. Reply.
    N Engl J Med. 2025;393:410.
    PubMed    
    
    
    
34. DE FREMONT GM, Le Guern V, Costedoat-Chalumeau N
    Efficacy and Safety of Obinutuzumab in Active Lupus Nephritis.
    N Engl J Med. 2025;393:409-410.
    PubMed    
    
    
    
35. KARASSA FB
    Efficacy and Safety of Obinutuzumab in Active Lupus Nephritis.
    N Engl J Med. 2025;393:409.
    PubMed    
    
    
    
36. SAHUTOGLU T
    Efficacy and Safety of Obinutuzumab in Active Lupus Nephritis.
    N Engl J Med. 2025;393:408-409.
    PubMed    
    
    
    
37. ANGELETTI A, Marasa M, Cravedi P
    Efficacy and Safety of Obinutuzumab in Active Lupus Nephritis.
    N Engl J Med. 2025;393:408.
    PubMed    
    
    
    June 2025
38. REICHMAN TW, Markmann JF, Odorico J, Witkowski P, et al
    Stem Cell-Derived, Fully Differentiated Islets for Type 1 Diabetes.
    N Engl J Med. 2025 Jun 20. doi: 10.1056/NEJMoa2506549.
    PubMed     Abstract available
    
    
    
39. WOLFE GI, Shelly S
    Myasthenia Gravis - Redemption for B-Cell Depletion.
    N Engl J Med. 2025;392:2382-2384.
    PubMed    
    
    
    
40. ZHANG L, Gao Z, Pan H, Li R, et al
    BCMA-Targeted T-Cell Engager for Autoimmune Hemolytic Anemia after CD19 CAR T-Cell Therapy.
    N Engl J Med. 2025;392:2282-2284.
    PubMed    
    
    
    May 2025
41. KOSTER MJ, Warrington KJ
    Upadacitinib - An Up-and-Comer for Treatment of Giant-Cell Arteritis.
    N Engl J Med. 2025;392:2062-2064.
    PubMed    
    
    
    
42. BARRATT J, Perkovic V, Rizk DV
    Alternative Complement Pathway, Iptacopan, and IgA Nephropathy. Reply.
    N Engl J Med. 2025;392:1976.
    PubMed    
    
    
    
43. ANGELETTI A, Marasa M, Cravedi P
    Alternative Complement Pathway, Iptacopan, and IgA Nephropathy.
    N Engl J Med. 2025;392:1976.
    PubMed    
    
    
    
44. POPPELAARS F, Faria B, Thurman JM
    Alternative Complement Pathway, Iptacopan, and IgA Nephropathy.
    N Engl J Med. 2025;392:1975.
    PubMed    
    
    
    
45. CALABRESI PA
    Progress toward Mitigating Disability Progression in Multiple Sclerosis.
    N Engl J Med. 2025;392:1966-1968.
    PubMed    
    
    
    
46. HOSHINO Y, Okamoto K, Ito N
    More on Acquired Osteomalacia and Autoantibodies against PHEX. Reply.
    N Engl J Med. 2025;392:1871-1872.
    PubMed    
    
    
    
47. MINISOLA S, Pepe J, Cipriani C
    More on Acquired Osteomalacia and Autoantibodies against PHEX.
    N Engl J Med. 2025;392:1871.
    PubMed    
    
    
    April 2025
48. FAVA A
    To B or Not to B - the Role of B-Cell Depletion in Lupus Nephritis.
    N Engl J Med. 2025;392:1545-1547.
    PubMed    
    
    
    
49. FOX RJ, Bar-Or A, Traboulsee A, Oreja-Guevara C, et al
    Tolebrutinib in Nonrelapsing Secondary Progressive Multiple Sclerosis.
    N Engl J Med. 2025 Apr 8. doi: 10.1056/NEJMoa2415988.
    PubMed     Abstract available
    
    
    
50. OH J, Arnold DL, Cree BAC, Ionete C, et al
    Tolebrutinib versus Teriflunomide in Relapsing Multiple Sclerosis.
    N Engl J Med. 2025 Apr 8. doi: 10.1056/NEJMoa2415985.
    PubMed     Abstract available
    
    
    
51. NOWAK RJ, Benatar M, Ciafaloni E, Howard JF Jr, et al
    A Phase 3 Trial of Inebilizumab in Generalized Myasthenia Gravis.
    N Engl J Med. 2025 Apr 8. doi: 10.1056/NEJMoa2501561.
    PubMed     Abstract available
    
    
    
52. BLOCKMANS D, Penn SK, Setty AR, Schmidt WA, et al
    A Phase 3 Trial of Upadacitinib for Giant-Cell Arteritis.
    N Engl J Med. 2025 Apr 2. doi: 10.1056/NEJMoa2413449.
    PubMed     Abstract available
    
    
    March 2025
53. STONE JH, Khosroshahi A, Zhang W, Della Torre E, et al
    Inebilizumab for Treatment of IgG4-Related Disease.
    N Engl J Med. 2025;392:1168-1177.
    PubMed     Abstract available
    
    
    February 2025
54. WANG JJ, Warkentin TE, Schonborn L, Wheeler MB, et al
    VITT-like Monoclonal Gammopathy of Thrombotic Significance.
    N Engl J Med. 2025 Feb 12. doi: 10.1056/NEJMoa2415930.
    PubMed     Abstract available
    
    
    
55. FURIE RA, Rovin BH, Garg JP, Santiago MB, et al
    Efficacy and Safety of Obinutuzumab in Active Lupus Nephritis.
    N Engl J Med. 2025 Feb 7. doi: 10.1056/NEJMoa2410965.
    PubMed     Abstract available
    
    
    January 2025
56. HOSHINO Y, Okamoto K, Ogawa T, Kato H, et al
    Acquired Osteomalacia Associated with Autoantibodies against PHEX.
    N Engl J Med. 2025;392:513-515.
    PubMed    
    
    
    October 2024
57. PERKOVIC V, Barratt J, Rovin B, Kashihara N, et al
    Alternative Complement Pathway Inhibition with Iptacopan in IgA Nephropathy.
    N Engl J Med. 2024 Oct 25. doi: 10.1056/NEJMoa2410316.
    PubMed     Abstract available
    
    
    
58. INGELFINGER JR
    Way Stations in Progress - Burgeoning Treatment Options for IgA Nephropathy.
    N Engl J Med. 2024 Oct 25. doi: 10.1056/NEJMe2413288.
    PubMed    
    
    
    
59. HEERSPINK HJL, Jardine M, Kohan DE, Lafayette RA, et al
    Atrasentan in Patients with IgA Nephropathy.
    N Engl J Med. 2024 Oct 25. doi: 10.1056/NEJMoa2409415.
    PubMed     Abstract available
    
    
    
60. CHANTRAPITAK J, Chuamanochan M
    Intertriginous Rash in Secondary Syphilis.
    N Engl J Med. 2024;391:e28.
    PubMed    
    
    
    
61. TOMAS NM, Hengel FE, Huber TB
    Autoantibodies Targeting Nephrin in Podocytopathies. Reply.
    N Engl J Med. 2024;391:1367-1368.
    PubMed    
    
    
    
62. BRUSCHI M, Angeletti A, Ghiggeri GM
    Autoantibodies Targeting Nephrin in Podocytopathies.
    N Engl J Med. 2024;391:1366.
    PubMed    
    
    
    
63. BERG AH, Karumanchi SA
    Autoantibodies Targeting Nephrin in Podocytopathies.
    N Engl J Med. 2024;391:1365-1366.
    PubMed    
    
    
    
64. GLEESON PJ, Monteiro RC
    Autoantibodies Targeting Nephrin in Podocytopathies.
    N Engl J Med. 2024;391:1365.
    PubMed    
    
    
    September 2024
65. RUSSO G, Alipour Tehrany Y
    Discoid Lupus Erythematosus.
    N Engl J Med. 2024;391:e24.
    PubMed    
    
    
    
66. SALVARANI C, Hunder GG, Brown RD Jr
    Primary Central Nervous System Vasculitis.
    N Engl J Med. 2024;391:1028-1037.
    PubMed    
    
    
    
67. HAGEN M, Bucci L, Boltz S, Nothling DM, et al
    BCMA-Targeted T-Cell-Engager Therapy for Autoimmune Disease.
    N Engl J Med. 2024;391:867-869.
    PubMed    
    
    
    
68. ALEXANDER T, Kronke J, Cheng Q, Keller U, et al
    Teclistamab-Induced Remission in Refractory Systemic Lupus Erythematosus.
    N Engl J Med. 2024;391:864-866.
    PubMed    
    
    
    August 2024
69. GRIFFIN H, Ceron-Gutierrez L, Gharahdaghi N, Ebrahimi S, et al
    Neutralizing Autoantibodies against Interleukin-10 in Inflammatory Bowel Disease.
    N Engl J Med. 2024;391:434-441.
    PubMed     Abstract available
    
    
    July 2024
70. LI M, Zhang Y, Jiang N, Ning C, et al
    Anti-CD19 CAR T Cells in Refractory Immune Thrombocytopenia of SLE.
    N Engl J Med. 2024;391:376-378.
    PubMed    
    
    
    
71. WANG WY, Lin MC
    Chilblain Lupus Erythematosus.
    N Engl J Med. 2024;391:e6.
    PubMed    
    
    
    
72. CHENG A, Holland SM
    Anti-Interleukin-23 Autoantibodies in Adult-Onset Immunodeficiency. Reply.
    N Engl J Med. 2024;391:189-190.
    PubMed    
    
    
    
73. ROSMARIN D, Amara S, Lebwohl M
    Anti-Interleukin-23 Autoantibodies in Adult-Onset Immunodeficiency.
    N Engl J Med. 2024;391:189.
    PubMed    
    
    
    
74. COHEN JM, Damsky W
    Anti-Interleukin-23 Autoantibodies in Adult-Onset Immunodeficiency.
    N Engl J Med. 2024;391:188-189.
    PubMed    
    
    
    
75. FEREDJ E, Cobat A, Casanova JL
    Anti-Interleukin-23 Autoantibodies in Adult-Onset Immunodeficiency.
    N Engl J Med. 2024;391:187-188.
    PubMed    
    
    
    June 2024
76. MANRIQUE-ACEVEDO C, Hirsch IB, Eckel RH
    Prevention of Cardiovascular Disease in Type 1 Diabetes. Reply.
    N Engl J Med. 2024;390:2227.
    PubMed    
    
    
    
77. MAAHS DM, Svensson J
    Prevention of Cardiovascular Disease in Type 1 Diabetes.
    N Engl J Med. 2024;390:2226-2227.
    PubMed    
    
    
    
78. WENSTEDT EFE, Vogt L
    Prevention of Cardiovascular Disease in Type 1 Diabetes.
    N Engl J Med. 2024;390:2226.
    PubMed    
    
    
    
79. CHEN Y, Xu Y, Li H, Sun T, et al
    A Novel Anti-CD38 Monoclonal Antibody for Treating Immune Thrombocytopenia.
    N Engl J Med. 2024;390:2178-2190.
    PubMed     Abstract available
    
    
    May 2024
80. WECHSLER ME, Fan Y, Merkel PA
    Benralizumab versus Mepolizumab for Eosinophilic Granulomatosis with Polyangiitis. Reply.
    N Engl J Med. 2024;390:1940.
    PubMed    
    
    
    
81. SUN R, Wei LJ
    Benralizumab versus Mepolizumab for Eosinophilic Granulomatosis with Polyangiitis.
    N Engl J Med. 2024;390:1939.
    PubMed    
    
    
    
82. OIKONOMOU V, Smith G, Constantine GM, Schmitt MM, et al
    The Role of Interferon-gamma in Autoimmune Polyendocrine Syndrome Type 1.
    N Engl J Med. 2024;390:1873-1884.
    PubMed     Abstract available
    
    
    
83. SU MA
    JAK Inhibition Immunotherapy for APS-1.
    N Engl J Med. 2024;390:1918-1921.
    PubMed    
    
    
    
84. HENGEL FE, Dehde S, Lasse M, Zahner G, et al
    Autoantibodies Targeting Nephrin in Podocytopathies.
    N Engl J Med. 2024 May 25. doi: 10.1056/NEJMoa2314471.
    PubMed     Abstract available
    
    
    
85. WANG JJ, Schonborn L, Warkentin TE, Chataway T, et al
    Antibody Fingerprints Linking Adenoviral Anti-PF4 Disorders.
    N Engl J Med. 2024;390:1827-1829.
    PubMed    
    
    
    
86. DOUGHTY CT, Schaefer PW, Brizzi K, Linnoila JJ, et al
    Case 14-2024: A 30-Year-Old Woman with Back Pain, Leg Stiffness, and Falls.
    N Engl J Med. 2024;390:1712-1719.
    PubMed    
    
    
    
87. MULLER F, Mackensen A, Schett G
    CAR T-Cell Therapy in Autoimmune Disease. Reply.
    N Engl J Med. 2024;390:1631-1632.
    PubMed    
    
    
    
88. HOWARD JF JR, Vu T, Mozaffar T
    CAR T-Cell Therapy in Autoimmune Disease.
    N Engl J Med. 2024;390:1629-1631.
    PubMed    
    
    
    
89. DE BENEDETTI F, Diomedi Camassei F, Locatelli F
    CAR T-Cell Therapy in Autoimmune Disease.
    N Engl J Med. 2024;390:1629.
    PubMed    
    
    
    
90. MERKT W, Lorenz HM, Schmitt M
    CAR T-Cell Therapy in Autoimmune Disease.
    N Engl J Med. 2024;390:1628-1629.
    PubMed    
    
    
    April 2024
91. MATHUR M, Barratt J, Suzuki Y
    Phase 2 Trial of Sibeprenlimab in Patients with IgA Nephropathy. Reply.
    N Engl J Med. 2024;390:1245-1246.
    PubMed    
    
    
    
92. BELMONT HM
    Phase 2 Trial of Sibeprenlimab in Patients with IgA Nephropathy.
    N Engl J Med. 2024;390:1245.
    PubMed    
    
    
    
93. MANRIQUE-ACEVEDO C, Hirsch IB, Eckel RH
    Prevention of Cardiovascular Disease in Type 1 Diabetes.
    N Engl J Med. 2024;390:1207-1217.
    PubMed    
    
    
    March 2024
94. NETEA MG, van de Veerdonk FL
    Anti-Interleukin-23 Autoantibodies and Severe Infections.
    N Engl J Med. 2024;390:1143-1146.
    PubMed    
    
    
    
95. CHENG A, Kashyap A, Salvator H, Rosen LB, et al
    Anti-Interleukin-23 Autoantibodies in Adult-Onset Immunodeficiency.
    N Engl J Med. 2024;390:1105-1117.
    PubMed     Abstract available
    
    
    
96. DRIVENES JL, Bygum A
    Spontaneous Oral Purpura in Immune Thrombocytopenia.
    N Engl J Med. 2024;390:1029.
    PubMed    
    
    
    
97. WECHSLER ME, Nair P, Terrier B, Walz B, et al
    Benralizumab versus Mepolizumab for Eosinophilic Granulomatosis with Polyangiitis.
    N Engl J Med. 2024;390:911-921.
    PubMed     Abstract available
    
    
    February 2024
98. MULLER F, Taubmann J, Bucci L, Wilhelm A, et al
    CD19 CAR T-Cell Therapy in Autoimmune Disease - A Case Series with Follow-up.
    N Engl J Med. 2024;390:687-700.
    PubMed     Abstract available
    
    
    
99. ISAACS JD
    CAR T Cells - A New Horizon for Autoimmunity?
    N Engl J Med. 2024;390:758-759.
    PubMed    
    
    
    
100. HAUSER SL
     Silencing Immune Dialogue in Multiple Sclerosis.
     N Engl J Med. 2024;390:662-663.
     PubMed    
     
     
     
101. VERMERSCH P, Granziera C, Mao-Draayer Y, Cutter G, et al
     Inhibition of CD40L with Frexalimab in Multiple Sclerosis.
     N Engl J Med. 2024;390:589-600.
     PubMed     Abstract available
     
     
     January 2024
102. DANDONA P, Chaudhuri A, Ghanim H
     More on Semaglutide in Early Type 1 Diabetes. Reply.
     N Engl J Med. 2024;390:292.
     PubMed    
     
     
     
103. GAGLIA JL, Laffel LM, Patti ME
     More on Semaglutide in Early Type 1 Diabetes.
     N Engl J Med. 2024;390:291.
     PubMed    
     
     
     
104. WEINRAUCH LA, D'Elia JA
     More on Semaglutide in Early Type 1 Diabetes.
     N Engl J Med. 2024;390:291.
     PubMed    
     
     
     
105. DEVRIES JH
     More on Semaglutide in Early Type 1 Diabetes.
     N Engl J Med. 2024;390:290.
     PubMed    
     
     
     
106. HADZIC N, Deheragoda M, Worth A, Bansal S, et al
     JAK Inhibition in STAT1 Gain-of-Function-Mediated Treatment-Resistant Autoimmune Hepatitis.
     N Engl J Med. 2024;390:284-286.
     PubMed    
     
     
     
107. LEE TTM, Bergford S, Murphy HR
     Automated Insulin Delivery during Pregnancy Complicated by Type 1 Diabetes. Reply.
     N Engl J Med. 2024;390:184.
     PubMed    
     
     
     
108. GRZYCH G, Kim I
     Automated Insulin Delivery during Pregnancy Complicated by Type 1 Diabetes.
     N Engl J Med. 2024;390:183-184.
     PubMed    
     
     
     
109. VIVANTI AJ, Benachi A, Voican A
     Automated Insulin Delivery during Pregnancy Complicated by Type 1 Diabetes.
     N Engl J Med. 2024;390:183.
     PubMed    
     
     
     
110. LEMLEY KV, Glassock RJ
     APRIL - Springtime for New IgA Nephropathy Therapy?
     N Engl J Med. 2024;390:80-81.
     PubMed    
     
     
     
111. LIU MJ, Li J
     Necrobiosis Lipoidica.
     N Engl J Med. 2024;390:70.
     PubMed    
     
     
     December 2023
112. ARJUNAN D, Bhadada SK
     Thyroid Dermopathy in Graves' Disease.
     N Engl J Med. 2023;389:2376.
     PubMed    
     
     
     
113. LUDVIGSSON J
     Immune Interventions at Onset of Type 1 Diabetes - Finally, a Bit of Hope.
     N Engl J Med. 2023;389:2199-2201.
     PubMed    
     
     
     
114. WAIBEL M, Wentworth JM, So M, Couper JJ, et al
     Baricitinib and beta-Cell Function in Patients with New-Onset Type 1 Diabetes.
     N Engl J Med. 2023;389:2140-2150.
     PubMed     Abstract available
     
     
     November 2023
115. EL-ZAATARI ZM
     Anti-Glomerular Basement Membrane Glomerulonephritis.
     N Engl J Med. 2023;389:1901.
     PubMed    
     
     
     
116. BUSSEL JB, Hou M, Cines DB
     Primary Immune Thrombocytopenia in Pregnancy. Reply.
     N Engl J Med. 2023;389:1728.
     PubMed    
     
     
     
117. TRAN BW, May KA, Pal N
     Primary Immune Thrombocytopenia in Pregnancy.
     N Engl J Med. 2023;389:1728.
     PubMed    
     
     
     
118. MATHUR M, Barratt J, Chacko B, Chan TM, et al
     A Phase 2 Trial of Sibeprenlimab in Patients with IgA Nephropathy.
     N Engl J Med. 2023 Nov 2. doi: 10.1056/NEJMoa2305635.
     PubMed     Abstract available
     
     
     October 2023
119. RAMOS EL, Dayan CM, Chatenoud L, Sumnik Z, et al
     Teplizumab and beta-Cell Function in Newly Diagnosed Type 1 Diabetes.
     N Engl J Med. 2023 Oct 18. doi: 10.1056/NEJMoa2308743.
     PubMed     Abstract available
     
     
     
120. LINDHOFF-LAST E, Schonborn L, Zaninetti C, Warkentin TE, et al
     Rescue Therapy in Chronic Prothrombotic Autoimmune Anti-PF4 Disorder.
     N Engl J Med. 2023;389:1339-1341.
     PubMed    
     
     
     
121. SPIERA RF, Unizony S, Warrington KJ, Sloane J, et al
     Sarilumab for Relapse of Polymyalgia Rheumatica during Glucocorticoid Taper.
     N Engl J Med. 2023;389:1263-1272.
     PubMed     Abstract available
     
     
     
122. LEE TTM, Collett C, Bergford S, Hartnell S, et al
     Automated Insulin Delivery in Women with Pregnancy Complicated by Type 1 Diabetes.
     N Engl J Med. 2023 Oct 5. doi: 10.1056/NEJMoa2303911.
     PubMed     Abstract available
     
     
     
123. GARG SK, Polsky S
     Technology Use and Glycemic Outcomes during Pregnancy with Type 1 Diabetes.
     N Engl J Med. 2023 Oct 5. doi: 10.1056/NEJMe2310798.
     PubMed    
     
     
     
124. ALETAHA D
     Polymyalgia Rheumatica - from Search for Efficacy to Choice of Strategy.
     N Engl J Med. 2023;389:1328-1329.
     PubMed    
     
     
     September 2023
125. BRODERICK L, Kastner DL
     Variant STAT4 and Treatment of an Autoinflammatory Syndrome. Reply.
     N Engl J Med. 2023;389:1151-1152.
     PubMed    
     
     
     
126. PASTORE S, De Martino E, Taddio A
     Variant STAT4 and Treatment of an Autoinflammatory Syndrome.
     N Engl J Med. 2023;389:1151.
     PubMed    
     
     
     
127. WANG WY, Cheng ST
     Sleeve Sign and Inverse Gottron's Papules in Anti-MDA5 Dermatomyositis.
     N Engl J Med. 2023;389:1032.
     PubMed    
     
     
     
128. DANDONA P, Chaudhuri A, Ghanim H
     Semaglutide in Early Type 1 Diabetes.
     N Engl J Med. 2023;389:958-959.
     PubMed    
     
     

Thank you for your interest in scientific medicine.

AMEDEO Autoimmune Disorders is free of charge. Privacy / Datenschutzerklärung | Imprint / Impressum